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Abstract
Lipoprotein(a) (Lp(a)) is an internationally recognized atherogenic risk factor which is inherited and not changed by
nutrition or physical activity. At present, only proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors may
modestly decrease its concentration (but not in all patients)—leading to a certain decrease in cardiovascular events (CVE)
in controlled studies. However, at present an elevation of Lp(a) is not a generally accepted indication for their use. More
effective is lipoprotein apheresis (LA) therapy with respect to both lowering Lp(a) levels and reduction of CVE. In the
future, an antisense oligonucleotide against apolipoprotein(a) will probably be available. Atherosclerosis in patients with
an elevation of Lp(a) may affect several vessel regions (carotids, aorta, coronaries, leg arteries). Thus, Lp(a) should be
measured in high-risk patients. These patients are usually cared for by their family doctors and by other specialists who
should closely cooperate. Lipidologists should decide whether costly therapies like PCSK9 inhibitors or LA should be
started. The main aim of current therapy is to optimize all other risk factors (LDL cholesterol, hypertension, diabetes
mellitus, body weight, renal insufficiency). Patients should be regularly monitored (lab data, heart, arteries). This paper
describes the duties of physicians of different specialties when caring for patients with high Lp(a) concentrations.
Keywords LDL cholesterol · Cardiovascular events · PCSK9 inhibitors · Physicians · Lipoprotein apheresis
Lipoprotein(a)—an internationally accepted
risk factor for cardiovascular events
Lipoprotein(a) (Lp(a)) was detected in 1963 [1]. It contains
an LDL particle to which apolipoprotein(a) is bound. In the
1990s studies showed an independent association between
elevated Lp(a) levels and the incidence of cardiovascular
events [2–4]. Recently, more epidemiological studies have
documented the atherogenic risk of increased Lp(a) con-
centrations [5–11]. This risk has been confirmed by studies
using a Mendelian randomization and genome-wide asso-
ciations [6, 12]. Mechanisms leading to atherosclerosis in-
clude direct atherogenic, proinflammatory and procoagulant
activities. However, they are not yet completely understood
[13]. It is of note that aortic valve stenosis is another pos-
sible consequence of high Lp(a) concentrations [14].
This article is part of the special issue “Lp(a) – Update 2018”
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Lipoprotein(a)—role in the general
population
The incidence of elevated Lp(a) concentrations in a given
population depends on the criterion which is used. Assum-
ing a rather high cut-off level, elevated Lp(a) levels were
observed in 10 to 20% of a given population [5, 12, 15].
Lp(a) is not influenced by nutritional factors or by physical
activity. A hormone deficit in postmenopausal women or
renal diseases may increase its concentration. Patients with
a familial hypercholesterolemia often show elevated Lp(a)
levels [16].
There is no doubt that not all subjects with high Lp(a)
levels show atherosclerotic lesions. The reasons are still
quite unclear. The composition of Lp(a) particles may be
different. Additional factors most probably play a role:
a positive family history with respect to early cardiovas-
cular events in first-degree relatives, cigarette smoking, hy-
pertension, elevation of low density lipoprotein cholesterol
(LDL-C), diabetes mellitus, or a procoagulative situation.
Thus, a healthy lifestyle and in many patients drug therapy
are required to avoid or to minimize these additional factors
in persons with an elevated Lp(a) risk.
Routine measurement of Lp(a) levels in a general popu-
lation is challenging due to financial reasons. Measurements
should focus on individuals with high atherogenic risk as
listed in Table 1; [17, 18].
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Table 1 Persons in whom Lp(a) should be measured [17, 18]
Premature acute coronary syndromes (as well as other atherosclerotic
cardiovascular disease (CVD) without apparent cause, e. g. crypto-
genic stroke)
Familial hypercholesterolemia
Family history of premature CVD or elevated Lp(a)
At least 5–7.5% 10-year risk of CVD (or at intermediate risk based on
other available risk scores)
Individuals with recurrent atherosclerotic cardiovascular events on
appropriate secondary prevention therapy
Lp(a) lipoprotein(a)
In 2017, Afshar and Thanassoulis [18] also suggested to
measure Lp(a) levels in patients with LDL-C levels above
3.5mmol/l (135mg/dl), who would otherwise not qualify
for statin therapy based on available guidelines.
At least in Germany, Lp(a) is recognized as an athero-
genic risk factor. In 2008 the Joint Federal Committee
(Gemeinsamer Bundesausschuss) accepted an isolated el-
evation of Lp(a) as an indication for lipoprotein apheresis
(LA) therapy [19] which is a prerequisite for being reim-
bursed by health insurance companies.
Fig. 1 depicts the authorities, institutions, societies, or-
ganizations, and persons involved in the management of
patients who were identified to have an increased cardio-
vascular risk due to elevated Lp(a) concentrations.
As Lp(a) is not yet well-known in the population and
especially among treating physicians, this paper aims to
give an overview about the current situation concerning the
diagnostic and therapeutic options.
Fig. 1 Institutions and persons involved in the care for patients with elevated Lp(a). LA lipoprotein apheresis, Lp(a) lipoprotein(a)
Lipoprotein(a)—role in the health care
system
Medical specialties playing a central role
Fig. 2 summarizes the medical specialties involved in the
care for patients with elevated Lp(a) levels. The vast ma-
jority of these patients are seen as outpatients, but severe
complications like myocardial infarction, stroke or vascular
interventions require hospitalization.
Physicians marked in red in Fig. 2 play a prominent role
when attending patients with high Lp(a) levels—their tasks
are described in more detail in the following.
Family doctors/general practitioners
The family doctor usually knows the family history of his
patients very well and thus can identify high-risk patients
whose first-degree relatives suffered from a cardiovascular
event at an early age (less than 60 years) or who have
high Lp(a) levels. He should also consider checking Lp(a)
levels of other family members who have not yet suffered
a cardiovascular event (Fig. 3).
Many family doctors regularly determine lipid concen-
trations of their patients, but some of them do not mea-
sure Lp(a)—mainly due to underestimation of the problem
“Lp(a)” or for financial restrictions. In high-risk patients,
lipids should be checked at least twice per year.
They should advise patients at risk to maintain a healthy
lifestyle (especially no smoking). Usually they pay attention
to possible concomitant diseases like hyperlipoproteinemia
(elevation of LDL-C or/and triglycerides (TG)), hyperten-
sion, diabetes mellitus, slight renal insufficiency. Further-
more, regular vascular and cardiological examinations are
K
Lipoprotein(a)—an interdisciplinary challenge
Fig. 2 Physicians involved in
the care for patients with ele-
vated Lp(a). Lp(a) lipoprotein(a)
Fig. 3 Role of family doctors.
Lp(a) lipoprotein(a)
important as well as a close cooperation with other spe-
cialists who may be contacted in case of complex situa-
tions, especially when progression of atherosclerosis has
been documented.
Lipidologists
The major aim of referring patients to lipidologists is to
improve the current risk situation with respect to lipoprotein
concentrations (Fig. 4). The goal is to reach internationally
recommended target levels for LDL-C—below 1.8mmol/l
(70mg/dl) in high-risk patients [17]. Statin therapy is often
modified (increase in dose or switch to another statin when
an intolerance is reported); sometimes ezetimibe is added.
However, these drugs do not exert a decreasing effect on
Lp(a) levels. Proprotein convertase subtilisin/kexin type 9
(PCSK9) inhibitors effectively reduce LDL-C levels and
can be started in therapy-resistant patients (Fig. 4).
After the withdrawal of nicotinic acid from the European
market, the following therapeutic options to reduce Lp(a)
levels are available:
1. PCSK9 inhibitors—decrease Lp(a) by a mean of about
20% (ranging between 0 and 44%); in some patients
a reduction cannot be achieved. In two prospective con-
trolled large studies, both evolocumab and alirocomab
induced a modest reduction of cardiovascular events
which was the consequence of decreasing Lp(a) lev-
els—independently of the effects on LDL-C [20]. Up to
now, an elevation of Lp(a) is no accepted indication for
this injection therapy.
2. LA—when comparing the Lp(a) levels before initiation
of the extracorporeal therapy with those measured during
weekly LA sessions (interval mean values)—a decrease
of about 50% is realistic. In two studies, cardiovascular
events were reduced by about 80% [21–23]. This corre-
sponds with the experience of other authors [24–27].
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Fig. 4 Role of lipidologists.
PCSK9 proprotein convertase
subtilisin/kexin type 9
Fig. 5 Role of cardiologists/angiologists. Lp(a) lipoprotein(a)
The Joint Federal Committee defined three conditions
before an LA therapy can be started:
a. Lp(a) value ≥60mg/dl (120nmol/l),
b. LDL-C in the optimal range (usually below 1.8mmol/l
[70mg/dl]),
c. A progression of atherosclerosis, either clinically or doc-
umented by imaging techniques [19].
Lipidologists are required to assess the total atherogenic
risk of a given patient before recommending LA treatment.
Some lipidologists are allowed to perform LA themselves.
Some health insurance companies require that their medical
services supervise the indication for LA therapy in a few
cases.
The ongoing lipid-modifying drug and LA therapy are
regarded as satisfactory when no progression of atheroscle-
rotic lesions (no new events) occurs. Usually patients are
seen in outpatient departments once every 3 months, in LA
centers weekly.
In the future, an antisense oligonucleotide against
apolipoprotein(a) will probably be available [28, 29]. A
phase III study will be started in 2020. However, outcome
data are needed before this therapeutic approach will play
a major role in daily practice.
Cardiologists/Angiologists
Some specialists do not measure Lp(a) concentrations; their
lab budget is rather restricted. However, an increasing num-
ber of them pay attention to this parameter in patients who
are at high cardiovascular risk (Table 1) and recommend
the family doctor to measure Lp(a) or to send the pa-
tient to a lipidological center. According to German regula-
tions, cardiologists/angiologists are authorized to prescribe
PCSK9 inhibitors. However, this is currently only done in
rare cases.
The usual investigations like cardiac ultrasound and er-
gometry do not provide an exact follow-up of coronary
atherosclerosis, while cardiac catheterization is only indi-
cated under defined conditions and may lead to adverse
events. Non-invasive techniques like computed tomogra-
phy (CT) or magnetic resonance imaging (MRI) will most
probably play an increasing role in the future. Aortic valve
stenosis, which can be seen in patients with a high Lp(a)
level, can be easily assessed by echocardiography.
As any vascular region may be affected by atherosclero-
sis it is important to examine limb and carotid arteries and
the aorta as well (Fig. 5).
Two important points should still be mentioned:
1. The current findings should always be compared with
previous data—to document or exclude progression of
atherosclerosis.
K
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Fig. 6 Role of nephrolo-
gists. Lp(a) lipoprotein(a),
PCSK9 proprotein convertase
subtilisin/kexin type 9
2. Patients should be offered a date for the next examina-
tion—the interval (usually annually or biannually) de-
pends on the severity of the arterial lesions. Most patients
have to be persuaded to be followed-up.
Of course, cardiac surgeons and vessel surgeons should
send their patients for Lp(a) evaluation following invasive
procedures.
Nephrologists
Renal diseases may increase Lp(a) concentrations. Other
lipids are also influenced.
Nephrologists should regularly measure lipid concentra-
tions and should treat disorders, if possible, in cooperation
with lipidological and vascular specialists (Fig. 6).
Nephrologists have the right to prescribe PCSK9 in-
hibitors and can apply for permission to perform LA
therapy. Of course, in apheresis patients attention should
also be paid to other risk factors. For application to start
or to continue LA therapy lipidological and cardiological/
angiological evaluations are required, which confirms the
relevance of the mentioned close cooperation with other
specialties (Fig. 2).
Nutritionists
Healthy nutrition is the basis for treating patients with lipid
disorders. Though Lp(a) is not changed by nutritional fac-
tors, LDL-C and TG can be improved. Thus all high-risk
patients with high Lp(a) levels should be advised.
Diabetologists, endocrinologists, specialists in internal
medicine
These specialists see patients with hyperlipidemia, metabolic
vascular syndrome, hypertension, diabetes mellitus, obesity,
and endocrine disorders. In these patients Lp(a) should be
measured. According to the official rules, physicians who
are specialists in both diabetology and endocrinology are
allowed to prescribe PCSK9 inhibitors. In complex situa-
tions, consultation with a lipidologist is recommended.
Laboratory medicals
It is an accepted opinion that measuring Lp(a) once in a life-
time is sufficient. However, as daily routine has shown that
Lp(a) levels vary; patients with high levels or those who
undergo Lp(a)-lowering therapy require repeated measure-
ments [30].
Neurologists
An ischemic stroke may be a consequence of an elevation
of Lp(a), even in children [31, 32]. Neurologists should
remember this cause, should measure Lp(a) and as a con-
sequence should forward these patients to vascular or lipi-
dological specialists.
Geriatricians
In very old patients Lp(a) does not have a prognostic sig-
nificance—high-risk patients already die at a younger age,
although with an increasing quality of medical care, the life
expectancy of patients with high Lp(a) levels will probably
increase. These patients will need continued medical care
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even beyond the age of 80 years in order to prevent new
cardiovascular events.
Gynecologists
Pregnancies affect lipid concentrations. Data on Lp(a) are
contradictory; sometimes an elevation was seen [33]. Some
authors suspected a relationship with pre-eclampsia [34].
It appears to be possible that Lp(a) induces abortions [35,
36]. Hormone replacement therapy post-menopause will de-
crease Lp(a) concentrations [37].
Pediatricians
An elevation of Lp(a) is an inherited disease. In children
of parents who suffered from cardiovascular complications
associated with high Lp(a) levels this parameter should
be measured, in older children an ultrasound examination
of the carotids is indicated. When Lp(a) levels are ele-
vated, follow-up assessments should be performed. Smok-
ing should be avoided. In children with familial hyperc-
holesterolemia appropriate therapeutic options should be
started (statins, apheresis, etc.) according to the existing
guidelines.
Psychotherapists
Patients who suffered from cardiovascular events may need
the help of a psychotherapist. The risk of new events is
rather high. On the other hand, relatives of affected patients
may worry about their own future.
Geneticists
The Lp(a) levels are determined by the number of kringles–IV
type 2 (low numbers are associated with high Lp(a) levels)
and by certain mutations in the Lp(a) gene. The atherogenic
risk of Lp(a) is depicted by its level—currently measuring
the kringles’ number or looking for gene mutations does
not play a role in medical practice. However, new findings
in the future may change this attitude.
Specialists in intensivemedicine
Patients with previous myocardial infarction or stroke may
have been in critical conditions needing intensive care.
After recovery Lp(a) measurements in these patients are
mandatory, especially in young age [38].
Activities of the German Lipid Association
(Lipid-Liga)
The German Lipid Association (Lipid-Liga) offers courses
to acquire the qualification of a lipidologist. Lp(a) is an
important topic in these courses. The number of these spe-
cialists is steadily increasing. However, there are regions
where no lipidologist is available yet.
Moreover, the German Lipid Association (Lipid-Liga)
proposes a certification of lipidological outpatient clinics or
lipidological competence centers and networks [39]. Close
cooperation with specialists working in the fields mentioned
in this paper is an important feature of these structures. This
Association also organizes symposia dealing with lipidolog-
ical issues, sometimes in cooperation with other societies
(internal medicine, cardiology, angiology, nephrology).
Conclusions
An elevation of Lp(a) concentrations is associated with
a high cardiovascular morbidity and mortality. High-risk
patients need special attention. The German government is
willing to spend money for these purposes and physicians
should use the available diagnostic and therapeutic oppor-
tunities.
All physicians caring for patients with lipid disorders
should attend meetings where lipidological topics are pre-
sented. Thus a high degree of qualification will be guar-
anteed. Close cooperation of different medical specialties
is needed. Lp(a) really represents an interdisciplinary chal-
lenge.
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